Iteos Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Iteos Therapeutics
ITOS Stock  USD 8.19  0.05  0.61%   
Iteos Therapeutics financial statements provide useful quarterly and yearly information to potential Iteos Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Iteos Therapeutics financial statements helps investors assess Iteos Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Iteos Therapeutics' valuation are summarized below:
Gross Profit
267.6 M
Market Capitalization
301 M
Enterprise Value Revenue
1.2621
Revenue
35 M
Earnings Share
(3.14)
There are over one hundred nineteen available fundamental trends for Iteos Therapeutics, which can be analyzed over time and compared to other ratios. All traders should confirm Iteos Therapeutics' regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 692.5 M in 2024. Enterprise Value is likely to gain to about 454.1 M in 2024

Iteos Therapeutics Total Revenue

11.97 Million

Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 3.4 M, Net Interest Income of 32.4 M or Interest Income of 32.4 M, as well as many indicators such as Price To Sales Ratio of 32.65, Dividend Yield of 0.0 or PTB Ratio of 0.65. Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Iteos Therapeutics Correlation against competitors.
For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

Iteos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets496.8 M667.6 M228.4 M
Slightly volatile
Other Current Liabilities15.4 M17.8 M7.3 M
Slightly volatile
Total Current Liabilities76.9 M40 M35.8 M
Slightly volatile
Total Stockholder Equity393.3 M575.2 M177.3 M
Slightly volatile
Other Liabilities55.3 M52.7 M16.7 M
Slightly volatile
Property Plant And Equipment Net11.3 M10.7 M3.3 M
Slightly volatile
Current Deferred Revenue2 M2.1 M20.6 M
Pretty Stable
Accounts Payable11.9 M11.3 M3.5 M
Slightly volatile
Cash323.2 M251.2 M150.8 M
Slightly volatile
Non Current Assets Total122.8 M116.9 M28 M
Slightly volatile
Non Currrent Assets Other3.5 M5.7 M2.9 M
Slightly volatile
Other Assets2.2 M1.5 M2.5 M
Pretty Stable
Cash And Short Term Investments434.8 M531.9 M198.8 M
Slightly volatile
Net Receivables5.1 M6.5 M2.8 M
Slightly volatile
Common Stock Total Equity31 K32.4 K63.6 K
Slightly volatile
Common Stock Shares Outstanding34.6 M35.8 M18.9 M
Slightly volatile
Liabilities And Stockholders Equity496.8 M667.6 M228.4 M
Slightly volatile
Non Current Liabilities Total26.6 M52.3 M15.4 M
Slightly volatile
Capital Surpluse342.5 M501 M165.7 M
Slightly volatile
Other Current Assets7.9 M12.2 M3.7 M
Slightly volatile
Other Stockholder Equity323.2 M463.8 M139.1 M
Slightly volatile
Total Liabilities103.5 M92.4 M51.1 M
Slightly volatile
Total Current Assets447.9 M550.7 M205.3 M
Slightly volatile
Capital Stock30.8 K32.4 K19 M
Slightly volatile
Non Current Liabilities Other60 M57.1 M13.3 M
Slightly volatile
Net Working Capital371 M510.6 M169.6 M
Slightly volatile
Short Term Debt1.9 M2.5 M2.1 M
Very volatile
Common Stock30.7 K32.4 K63.5 K
Slightly volatile
Property Plant Equipment1.8 M2.4 M1.4 M
Slightly volatile
Short and Long Term Debt Total5.9 M6.1 M5.4 M
Pretty Stable
Property Plant And Equipment Gross8.9 M15.1 M5.3 M
Slightly volatile

Iteos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income32.4 M30.9 M5 M
Slightly volatile
Depreciation And Amortization1.3 M898 K1 M
Pretty Stable
Selling General Administrative29.9 M50.4 M15.2 M
Slightly volatile
Other Operating Expenses86.5 M163.7 M46.7 M
Slightly volatile
Research Development61.7 M113.3 M35.7 M
Slightly volatile
Total Operating Expenses86.5 M163.7 M46.7 M
Slightly volatile
Reconciled Depreciation724.4 K894 K581 K
Slightly volatile
Cost Of Revenue763.8 K898 K649 K
Slightly volatile
Preferred Stock And Other Adjustments199.2 K224.1 K244 K
Slightly volatile

Iteos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation28.4 M27 M6.5 M
Slightly volatile
Begin Period Cash Flow280.7 M285 M130.8 M
Slightly volatile
Other Cashflows From Financing Activities1.1 M1.1 M23.2 M
Pretty Stable
Depreciation725.1 K898 K581.3 K
Slightly volatile
Capital Expenditures3.1 M3 M754 K
Slightly volatile
Total Cash From Financing Activities1.1 M1.1 M38.8 M
Very volatile
End Period Cash Flow323.4 M251.5 M150.9 M
Slightly volatile
Net Borrowings1.6 M953.1 K3.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.6531.09258.2233
Slightly volatile
PTB Ratio0.650.68089.1422
Pretty Stable
Days Sales Outstanding19818836.2047
Slightly volatile
Book Value Per Share8.2816.08425.7629
Slightly volatile
Stock Based Compensation To Revenue2.252.14540.3304
Slightly volatile
Capex To Depreciation3.473.30291.0515
Slightly volatile
PB Ratio0.650.68089.1422
Pretty Stable
EV To Sales12.2111.63093.5369
Slightly volatile
Payables Turnover0.07550.07950.2935
Slightly volatile
Sales General And Administrative To Revenue4.24.00130.6517
Slightly volatile
Research And Ddevelopement To Revenue9.458.99561.3917
Slightly volatile
Capex To Revenue0.250.23550.0353
Slightly volatile
Cash Per Share9.2514.87316.8001
Slightly volatile
Days Payables Outstanding4.8 K4.6 K1.8 K
Slightly volatile
Current Ratio8.1313.76157.1222
Slightly volatile
Tangible Book Value Per Share8.2816.08425.7629
Slightly volatile
Receivables Turnover1.841.937730.3931
Very volatile
Graham Number18.9333.761516.2775
Slightly volatile
Shareholders Equity Per Share8.2816.08425.7629
Slightly volatile
Debt To Equity0.00130.00220.0014
Pretty Stable
Capex Per Share0.08710.08290.0354
Slightly volatile
Graham Net Net7.0112.42694.7201
Slightly volatile
Revenue Per Share0.330.35228.3873
Slightly volatile
Interest Debt Per Share0.01780.0350.0147
Slightly volatile
Debt To Assets0.0010.00190.001
Slightly volatile
Price Book Value Ratio0.650.68089.1422
Pretty Stable
Days Of Payables Outstanding4.8 K4.6 K1.8 K
Slightly volatile
Ebt Per Ebit0.720.72160.8572
Pretty Stable
Company Equity Multiplier1.611.16061.6609
Slightly volatile
Total Debt To Capitalization0.00130.00220.0014
Pretty Stable
Debt Equity Ratio0.00130.00220.0014
Pretty Stable
Quick Ratio8.1313.76157.1259
Slightly volatile
Net Income Per E B T1.011.03310.9692
Slightly volatile
Cash Ratio5.896.27725.6758
Pretty Stable
Days Of Sales Outstanding19818836.2047
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.02861.0204
Slightly volatile
Price To Book Ratio0.650.68089.1422
Pretty Stable
Fixed Asset Turnover1.111.173640.0545
Slightly volatile
Debt Ratio0.0010.00190.001
Slightly volatile
Price Sales Ratio32.6531.09258.2233
Slightly volatile
Asset Turnover0.01790.01890.3378
Slightly volatile
Gross Profit Margin1.070.92870.9983
Very volatile
Price Fair Value0.650.68089.1422
Pretty Stable

Iteos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap692.5 M624.9 M452.7 M
Slightly volatile
Enterprise Value454.1 M372.8 M312.3 M
Slightly volatile

Iteos Fundamental Market Drivers

Forward Price Earnings12.5628
Cash And Short Term Investments531.9 M

Iteos Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Iteos Therapeutics Financial Statements

Iteos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M2 M
Total Revenue12.6 M12 M
Cost Of Revenue898 K763.8 K
Stock Based Compensation To Revenue 2.15  2.25 
Sales General And Administrative To Revenue 4.00  4.20 
Research And Ddevelopement To Revenue 9.00  9.45 
Capex To Revenue 0.24  0.25 
Revenue Per Share 0.35  0.33 
Ebit Per Revenue(12.00)(11.40)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY